S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00896922|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : February 28, 2017
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
PURPOSE: This laboratory study is examining biological markers in patients with follicular lymphoma treated on clinical trial SWOG-8809, SWOG-9800, or SWOG-9911.
|Condition or disease||Intervention/treatment|
|Lymphoma||Genetic: microarray analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- Determine the prognostic significance of MUM-1, lymphoma-associated macrophages, and regulatory T cells in patients with follicular lymphoma treated on clinical trials SWOG-8809, SWOG-9800, or SWOG-9911 representing pre- and post-monoclonal antibody therapy protocols.
- Determine whether these factors have similar prognostic significance in patients treated with chemotherapy alone vs chemotherapy and monoclonal antibody therapy on these clinical trials.
OUTLINE: This is a multicenter study.
Previously collected tissue samples from patients are analyzed by immunohistochemistry, gene expression profiling, and quantitative analysis for MUM1 expression, lymphoma-associated macrophages, FOXP3-positive regulatory T cells, CD68, and CD163.
PROJECTED ACCRUAL: A total of 318 samples will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||180 participants|
|Official Title:||Assessment of MUM1 Expression, Lymphoma-Associated Macrophages, and Regulatory T-Cells in Follicular Lymphoma: Prognostic Markers in SWOG S8809 and S9800/S9911 Trials Representing Pre-and Post-Monoclonal Antibody Therapy Protocols|
|Study Start Date :||January 2007|
|Actual Primary Completion Date :||October 2009|
|Actual Study Completion Date :||October 2009|
- Prognostic significance of MUM-1, lymphoma-associated macrophages, and regulatory T cells [ Time Frame: Retrospective ]
- Comparison of prognostic significance in patients treated with chemotherapy alone vs chemotherapy and monoclonal antibody therapy [ Time Frame: Retrospective ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00896922
|Study Chair:||John W. Sweetenham, MD||The Cleveland Clinic|